Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1cd7029ec038fa78d4b371f9bf08e9e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-0041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00791 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00642 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-0071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2218-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2017-00575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-0075 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-1206 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-1233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-1492 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-12 |
filingDate |
2014-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ab1ec64471f610e0efd385e718efb8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd02d2981f735533f31ba2cb0562eae9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b345a056ae6068789ee86cc25edb92e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5750b3cd076b1bf6e152162617ced861 |
publicationDate |
2014-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2014324040-A1 |
titleOfInvention |
Controlling Coagulum Formation |
abstract |
Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures. |
priorityDate |
2006-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |